跳至主要内容
临床试验/ITMCTR2100005376
ITMCTR2100005376尚未招募3 期

Efficacy and safety of Binafuxi granule in the treatment of common cold (heat syndrome): a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial

West China Hospital, Sichuan University0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 65(—)
性别
Male

入选标准

  • (1) Diagnosis of common cold according to Western medicine and symptom presenting within 48 hours;
  • (2) With fever and body temperature between 37.5 degree Celsius and 39 degrees Celsius;
  • (3) Diagnosis of common cold with heat syndrome according to traditional Uighur medicine;
  • (4) Aged between 18 and 65 years;
  • (5) Willing to participate and sign the informed consent.

排除标准

  • (1) Diagnosis of common cold with cold syndrome according to traditional Uighur medicine;
  • (2) Patients with influenza, acute or chronic rhinitis, acutel sinusitis, suppurative tonsillitis, pneumonia and Tuberculosis;
  • (3) white blood cell count>11.0 × 10^9/L and/or neutrophils percentae > 80%;
  • (4) Patients who are taking any medication to treat common cold;
  • (5) Patients with gastrointestinal discomfort symptoms such as acute and chronic diarrhea;
  • (6) Patients with serious primary diseases of the cardiovascular, pulmonary, kidney, liver, neurological and hematological system;
  • (7) Pregnant women, lactating women, or women who have a birth plan;
  • (8) Patients with allergic constitution or being allergic to the study drug;
  • (9) Patients who are participating in or have participated in another drug clinical trial within the last 3 months;
  • (10) Patients who have been judged by the investigator as inappropriate to participate in the clinical trial.

研究者

发起方
West China Hospital, Sichuan University

相似试验